Ion Exchange (India) Limited has informed the stock exchanges that it has not been identified as a Large Corporate (LC) as on March 31, 2026, under the framework governing fund raising through the issuance of debt securities. The disclosure was submitted to both BSE Limited and National Stock Exchange of India Limited on May 15, 2026.

Regulatory Background

The disclosure was made in compliance with two SEBI circulars that establish the framework for identifying Large Corporates and their obligations with respect to debt securities issuance:

These circulars outline the applicability framework under which listed entities are assessed for their classification as Large Corporates, with implications for mandatory fund raising through debt markets.

Company Confirmation

Ion Exchange (India) Limited confirmed in its filing that, as per the applicability framework provided in the aforementioned SEBI circulars, the company does not meet the criteria to be classified as a Large Corporate as on March 31, 2026. This regulatory disclosure is a periodic compliance requirement for listed entities under SEBI's framework.

The filing was authorised and digitally signed by the following officials:

Both signatories affixed their digital signatures on May 15, 2026, confirming the authenticity and accuracy of the disclosure on behalf of Ion Exchange (India) Limited.

About the Filing

The disclosure was addressed to the Corporate Relationship Department of BSE Limited at P. J. Towers, Dalal Street, Mumbai, and to National Stock Exchange of India Limited at Exchange Plaza, Bandra Kurla Complex, Mumbai. Ion Exchange (India) Limited is registered under CIN: L74999MH1964PLC014258, with its registered office at Ion House, Dr. E. Moses Road, Mahalaxmi, Mumbai – 400011, India.

Ion Exchange (India) Limited has executed a Technology Transfer Agreement with MANN + HUMMEL for the manufacture of PVDF Ultrafiltration (UF) membranes and Integrated Membrane Bioreactor (MBR) systems. The agreement was announced pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on April 29, 2026.

Agreement Details

The collaboration encompasses both domestic and international operations. Under the agreement, MANN + HUMMEL will transfer technology for the production of advanced PVDF hollow fiber ultrafiltration membranes with integrated UltraSKID systems, followed by technology transfer for Membrane Bioreactor solutions for deployment in India.

Production and Strategic Benefits

Production will be conducted at Ion Exchange's expanded HYDRAMEM® membrane manufacturing facility in Goa. The agreement includes the transfer of technical know-how, covering manufacturing processes, formulations, and best practices. Ion Exchange will manufacture, undertake system integration, and commercialize PVDF hollow fiber ultrafiltration membranes along with integrated UltraSKID systems based on MANN+HUMMEL's advanced technology.

Expected Benefits and Rationale

The collaboration strengthens Ion Exchange's HYDRAMEM® solutions to offer an integrated portfolio of membrane-based technologies, including Ultrafiltration (UF), Reverse Osmosis (RO) and Membrane Bioreactor (MBR) systems. The strategic partnership aims to enable the delivery of globally benchmarked membrane technology manufactured locally, reduce import dependence, and ensure improved supply reliability with faster delivery timelines for customers.

Regulatory Compliance Details

The agreement has been entered into in the ordinary course of business and is expected to support the Company's long-term strategic and technological objectives. The disclosure was made in compliance with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, providing comprehensive details of the strategic technology transfer and manufacturing collaboration.